{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:50:56Z","timestamp":1791258656875,"version":"4.1.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-026-09205-y","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:03:56Z","timestamp":1791255836000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ataxia-Telangiectasia, DNA Repair Deficits, Immune Dysfunction, and Cancer: A Review of Mechanisms, Clinical Presentations, and Emerging Therapies"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0696-049X","authenticated-orcid":false,"given":"Birinder Singh","family":"Doad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9797-9953","authenticated-orcid":false,"given":"Gustavo","family":"Borges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6261-6351","authenticated-orcid":false,"given":"Yusheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-1620","authenticated-orcid":false,"given":"Danny","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-2516","authenticated-orcid":false,"given":"Susan Patricia","family":"Lees-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6893-3366","authenticated-orcid":false,"given":"Luis","family":"Murgu\u00eda-Favela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-6391","authenticated-orcid":false,"given":"Eyal","family":"Grunebaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-477X","authenticated-orcid":false,"given":"Aru","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"8","key":"9205_CR1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/sj.embor.7400210","volume":"5","author":"PJ McKinnon","year":"2004","unstructured":"McKinnon PJ (2004) ATM and ataxia telangiectasia. EMBO Rep 5(8):772\u2013776. https:\/\/doi.org\/10.1038\/sj.embor.7400210 PubMed PMID: 15289825; PubMed Central PMCID: PMC1299121","journal-title":"EMBO Rep"},{"key":"9205_CR2","unstructured":"Riboldi G, Samanta M, Asuncion R, Frucht S, Ataxia-Telangiectasia (2026) Updated 2024 Mar 6. In: StatPearls [Internet]: Treasure Island (FL): StatPearls Publishing. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519542\/"},{"issue":"5","key":"9205_CR3","first-page":"573","volume":"39","author":"M Swift","year":"1986","unstructured":"Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT (1986) The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 39(5):573\u2013583 PubMed PMID: 3788973; PubMed Central PMCID: PMC1684065","journal-title":"Am J Hum Genet"},{"issue":"3","key":"9205_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrc1011","volume":"3","author":"Y Shiloh","year":"2003","unstructured":"Shiloh Y (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3(3):155\u2013168. https:\/\/doi.org\/10.1038\/nrc1011 PubMed PMID: 12612651","journal-title":"Nat Rev Cancer"},{"key":"9205_CR5","unstructured":"Veenhuis S, vON, Weemaes C, Kamsteeg EJ, Willemsen M 1999 Ataxia-Telangiectasia. [Internet]: GeneReviews\u00ae, [cited Updated 2025 Dec 4]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK26468\/"},{"issue":"1","key":"9205_CR6","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1200\/JCO.2011.40.1430","volume":"31","author":"MD DeWire","year":"2012","unstructured":"DeWire MD, Beltran C, Boop FA, Helton KJ, Ellison DW, McKinnon PJ et al (2012) Radiation therapy and adjuvant chemotherapy in a patient with a malignant glioneuronal tumor and underlying ataxia telangiectasia: a case report and review of the literature. J Clin Oncol 31(1):e12\u2013e14 PubMed PMID: 22689803; PubMed Central PMCID: PMC4881371","journal-title":"J Clin Oncol"},{"issue":"8","key":"9205_CR7","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/0360-3016(87","volume":"13","author":"RM Hart","year":"1987","unstructured":"Hart RM, Kimler BF, Evans RG, Park CH (1987) Radiotherapeutic management of medulloblastoma in a pediatric patient with ataxia telangiectasia. Int J Radiat Oncol Biol Phys 13(8):1237\u20131240. https:\/\/doi.org\/10.1016\/0360-3016(87)90200-8. PubMed PMID: 3610711","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"9205_CR8","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/adc.2006.094268","volume":"91","author":"TO Crawford","year":"2006","unstructured":"Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM (2006) Survival probability in ataxia telangiectasia. Arch Dis Child 91(7):610\u2013611 10.1136\/adc.2006.094268. PubMed PMID: 16790721; PubMed Central PMCID: PMC2082822","journal-title":"Arch Dis Child"},{"issue":"2","key":"9205_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jaci.2024.10.023","volume":"155","author":"A Magnarelli","year":"2025","unstructured":"Magnarelli A, Liu Q, Wang F, Peng XP, Wright J, Oak N et al (2025) Prevalence and outcomes of cancer and treatment-associated toxicities for patients with ataxia telangiectasia. J Allergy Clin Immunol 155(2):640\u2013649 Epub 20241108. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.023","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"9205_CR10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41580-021-00394-2","volume":"22","author":"JH Lee","year":"2021","unstructured":"Lee JH, Paull TT (2021) Cellular functions of the protein kinase ATM and their relevance to human disease. Nat Rev Mol Cell Biol 22(12):796\u2013814 Epub 20210824. https:\/\/doi.org\/10.1038\/s41580-021-00394-2","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9205_CR11","doi-asserted-by":"publisher","first-page":"1200466","DOI":"10.3389\/fcell.2023.1200466","volume":"11","author":"D Xie","year":"2023","unstructured":"Xie D, Jiang B, Wang S, Wang Q, Wu G (2023) The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer. Front Cell Dev Biol 11:1200466 PubMed PMID: 37305685; PubMed Central PMCID: PMC10248030","journal-title":"Front Cell Dev Biol"},{"key":"9205_CR12","doi-asserted-by":"publisher","unstructured":"Bakkenist CJ, Kastan MB (2003) DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421(6922):499\u2013506. https:\/\/doi.org\/10.1038\/nature01368. PubMed PMID: 12556884","DOI":"10.1038\/nature01368"},{"issue":"6","key":"9205_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4161\/cc.4.6.1715","volume":"4","author":"TT Paull","year":"2005","unstructured":"Paull TT, Lee JH (2005) The Mre11\/Rad50\/Nbs1 complex and its role as a DNA double-strand break sensor for ATM. Cell Cycle 4(6):737\u2013740 Epub 20050606. https:\/\/doi.org\/10.4161\/cc.4.6.1715","journal-title":"Cell Cycle"},{"issue":"4","key":"9205_CR14","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.21873\/anticanres.16931","volume":"44","author":"CC Tseng","year":"2024","unstructured":"Tseng CC, Ku MH, Wu YC, Huang WL, Wu WM, Pai CH et al (2024) Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer. Anticancer Res 44(4):1353\u20131364. https:\/\/doi.org\/10.21873\/anticanres.16931 PubMed PMID: 38538001","journal-title":"Anticancer Res"},{"key":"9205_CR15","doi-asserted-by":"publisher","first-page":"103647","DOI":"10.1016\/j.dnarep.2024.103647","volume":"135","author":"TT Paull","year":"2024","unstructured":"Paull TT, Woolley PR (2024) A-T neurodegeneration and DNA damage-induced transcriptional stress. DNA Repair (Amst) 135:103647 Epub 20240215. doi: 10.1016\/j.dnarep.2024.103647. PubMed PMID: 38377644; PubMed Central PMCID: PMC11707827","journal-title":"DNA Repair (Amst)"},{"key":"9205_CR16","doi-asserted-by":"publisher","first-page":"102268","DOI":"10.1016\/j.tranon.2024.102268","volume":"52","author":"JH Lee","year":"2025","unstructured":"Lee JH (2025) ATM in immunobiology: From lymphocyte development to cancer immunotherapy. Transl Oncol 52:102268 Epub 20250102. doi: 10.1016\/j.tranon.2024.102268. PubMed PMID: 39752906; PubMed Central PMCID: PMC11754496","journal-title":"Transl Oncol"},{"key":"9205_CR17","unstructured":"National Library of Medicine ATM gene MedlinePlus Genetics: National Library of Medicine; 2022 [2026-03-24]. Available from: https:\/\/medlineplus.gov\/genetics\/gene\/atm\/"},{"issue":"1","key":"9205_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1158\/1055-9965.epi-082-3","volume":"13","author":"L Ai","year":"2004","unstructured":"Ai L, Vo QN, Zuo C, Li L, Ling W, Suen JY et al (2004) Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev 13(1):150\u2013156. https:\/\/doi.org\/10.1158\/1055-9965.epi-082-3 PubMed PMID: 14744748","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"9205_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13023-016-0543-7","volume":"11","author":"C Rothblum-Oviatt","year":"2016","unstructured":"Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM (2016) Ataxia telangiectasia: a review. Orphanet J Rare Dis 11(1):159 Epub 20161125. https:\/\/doi.org\/10.1186\/s13023-016-0543-7","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"9205_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.tibs.2011.10.002","volume":"37","author":"S Ditch","year":"2012","unstructured":"Ditch S, Paull TT (2012) The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem Sci 37(1):15\u201322 Epub 20111111. https:\/\/doi.org\/10.1016\/j.tibs.2011.10.002","journal-title":"Trends Biochem Sci"},{"key":"9205_CR21","doi-asserted-by":"publisher","first-page":"101511","DOI":"10.1016\/j.redox.2020.101511","volume":"32","author":"JH Lee","year":"2020","unstructured":"Lee JH, Paull TT (2020) Mitochondria at the crossroads of ATM-mediated stress signaling and regulation of reactive oxygen species. Redox Biol 32:101511 Epub 20200321. doi: 10.1016\/j.redox.2020.101511. PubMed PMID: 32244177; PubMed Central PMCID: PMC7115119","journal-title":"Redox Biol"},{"key":"9205_CR22","doi-asserted-by":"publisher","unstructured":"Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT (2010) ATM activation by oxidative stress. Science 330(6003):517\u2009\u2013\u200921. https:\/\/doi.org\/10.1126\/science.1192912. PubMed PMID: 20966255","DOI":"10.1126\/science.1192912"},{"issue":"19","key":"9205_CR23","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.4161\/15384101.2014.959849","volume":"13","author":"AT Tubbs","year":"2014","unstructured":"Tubbs AT, Sleckman BP (2014) ATM deficiency: revealing the pathways to cancer. Cell Cycle 13(19):2992 : 10.4161\/15384101.2014.959849. PubMed PMID: 25486558; PubMed Central PMCID: PMC4614887","journal-title":"Cell Cycle"},{"issue":"1","key":"9205_CR24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/onc.2012.577","volume":"33","author":"LP Vaites","year":"2014","unstructured":"Vaites LP, Lian Z, Lee EK, Yin B, DeMicco A, Bassing CH et al (2014) ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis. Oncogene 33(1):129\u2013133 Epub 20130114. https:\/\/doi.org\/10.1038\/onc.2012.577","journal-title":"Oncogene"},{"issue":"20","key":"9205_CR25","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-17-0634","volume":"77","author":"L Perkhofer","year":"2017","unstructured":"Perkhofer L, Schmitt A, Romero Carrasco MC, Ihle M, Hampp S, Ruess DA et al (2017) ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Cancer Res 77(20):5576\u20135590 Epub 20170808. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0634","journal-title":"Cancer Res"},{"issue":"1","key":"9205_CR26","doi-asserted-by":"publisher","first-page":"11144","DOI":"10.1038\/s41598-017-11661-8","volume":"7","author":"Y Drosos","year":"2017","unstructured":"Drosos Y, Escobar D, Chiang MY, Roys K, Valentine V, Valentine MB et al (2017) ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer. Sci Rep 7(1):11144 Epub 20170911. https:\/\/doi.org\/10.1038\/s41598-017-11661-8","journal-title":"Sci Rep"},{"issue":"1","key":"9205_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13023-021-01904-3","volume":"16","author":"M Tatfi","year":"2021","unstructured":"Tatfi M, Perthame E, Hillion KH, Dillies MA, Menager H, Hermine O et al (2021) Gene expression analysis in EBV-infected ataxia-telangiectasia cell lines by RNA-sequencing reveals protein synthesis defect and immune abnormalities. Orphanet J Rare Dis 16(1):288 Epub 20210628. https:\/\/doi.org\/10.1186\/s13023-021-01904-3","journal-title":"Orphanet J Rare Dis"},{"issue":"6262","key":"9205_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/bmj.282.6262.425","volume":"282","author":"AK Saemundsen","year":"1981","unstructured":"Saemundsen AK, Berkel AI, Henle W, Henle G, Anvret M, Sanal O et al (1981) Epstein-Barr-virus-carrying lymphoma in a patient with ataxia-telangiectasia. Br Med J (Clin Res Ed) 282(6262):425\u2013427. https:\/\/doi.org\/10.1136\/bmj.282.6262.425 PubMed PMID: 6257325; PubMed Central PMCID: PMC1504242","journal-title":"Br Med J (Clin Res Ed)"},{"key":"9205_CR29","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.3389\/fimmu.2018.03060","volume":"9","author":"M Tatfi","year":"2018","unstructured":"Tatfi M, Hermine O, Suarez F (2018) Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle? Front Immunol 9:3060 Epub 20190104. https:\/\/doi.org\/10.3389\/fimmu.2018.03060","journal-title":"Front Immunol"},{"issue":"3","key":"9205_CR30","doi-asserted-by":"publisher","first-page":"e28126","DOI":"10.1002\/pbc.28126","volume":"67","author":"JD Rubinstein","year":"2020","unstructured":"Rubinstein JD, Burns K, Absalon M, Lutzko C, Leemhuis T, Chandra S et al (2020) EBV-directed viral-specific T-lymphocyte therapy for the treatment of EBV-driven lymphoma in two patients with primary immunodeficiency and DNA repair defects. Pediatr Blood Cancer 67(3):e28126 Epub 20191218. https:\/\/doi.org\/10.1002\/pbc.28126","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"9205_CR31","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1017\/s0317167100007794","volume":"36","author":"RA Yanofsky","year":"2009","unstructured":"Yanofsky RA, Seshia SS, Dawson AJ, Stobart K, Greenberg CR, Booth FA et al (2009) Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment. Can J Neurol Sci 36(4):462\u2013467. https:\/\/doi.org\/10.1017\/s0317167100007794 PubMed PMID: 19650357","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"9205_CR32","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/mgg3.72","volume":"2","author":"K Nakamura","year":"2014","unstructured":"Nakamura K, Fike F, Haghayegh S, Saunders-Pullman R, Dawson AJ, D\u00f6rk T et al (2014) A-TWinnipeg: Pathogenesis of rare ATM missense mutation c.6200C\u2009>\u2009A with decreased protein expression and downstream signaling, early-onset dystonia, cancer, and life-threatening radiotoxicity. Mol Genet Genomic Med 2(4):332\u2013340 Epub 20140313. https:\/\/doi.org\/10.1002\/mgg3.72","journal-title":"Mol Genet Genomic Med"},{"issue":"6","key":"9205_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/MPH.0000000000001005","volume":"40","author":"SA Upadhyaya","year":"2018","unstructured":"Upadhyaya SA, Mody R, Walkovich K, Hutchinson RJ, Sandlund JT, Connelly JA (2018) Ataxia Telangiectasia and Cancer Predisposition: Challenges in Management. J Pediatr Hematol Oncol 40(6):483\u2013486 .0000000000001005. PubMed PMID: 29200166","journal-title":"J Pediatr Hematol Oncol"},{"key":"9205_CR34","doi-asserted-by":"publisher","unstructured":"Sinha S, Ng V, Novaj A, Zhu Y, Yazaki S, Pei X et al (2025) The cold immunological landscape of ATM-deficient cancers. J Immunother Cancer 13(5). https:\/\/doi.org\/10.1136\/jitc-2024-010548. PubMed PMID: 40350205; PubMed Central PMCID: PMC12067784","DOI":"10.1136\/jitc-2024-010548"},{"issue":"9","key":"9205_CR35","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/jnci\/djy028","volume":"110","author":"B Weigelt","year":"2018","unstructured":"Weigelt B, Bi R, Kumar R, Blecua P, Mandelker DL, Geyer FC et al (2018) The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. J Natl Cancer Inst 110(9):1030\u20131034. https:\/\/doi.org\/10.1093\/jnci\/djy028 PubMed PMID: 29506079; PubMed Central PMCID: PMC6136925","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"9205_CR36","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","volume":"127","author":"F Nadeu","year":"2016","unstructured":"Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M et al (2016) Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 127(17):2122\u20132130 Epub 20160202. https:\/\/doi.org\/10.1182\/blood-2015-07-659144","journal-title":"Blood"},{"issue":"1","key":"9205_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3324\/haematol.2011.057109","volume":"97","author":"D Rossi","year":"2012","unstructured":"Rossi D, Gaidano G (2012) ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter. Haematologica 97(1):5\u20138 doi: 10.3324\/haematol.2011.057109. PubMed PMID: 22210328; PubMed Central PMCID: PMC3248924","journal-title":"Haematologica"},{"issue":"6","key":"9205_CR38","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jmcb\/mju045","volume":"6","author":"L Zannini","year":"2014","unstructured":"Zannini L, Delia D, Buscemi G (2014) CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol 6(6):442\u2013457 Epub 20141117. https:\/\/doi.org\/10.1093\/jmcb\/mju045","journal-title":"J Mol Cell Biol"},{"issue":"10","key":"9205_CR39","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar JC, Cortez D, Cimprich KA (2017) The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol 18(10):622\u2013636 Epub 20170816. https:\/\/doi.org\/10.1038\/nrm.2017.67","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"9205_CR40","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","volume":"14","author":"Q Liu","year":"2000","unstructured":"Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K et al (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint. Genes Dev 14(12):1448\u20131459 PubMed PMID: 10859164; PubMed Central PMCID: PMC316686","journal-title":"Genes Dev"},{"issue":"14","key":"9205_CR41","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.4161\/cc.9.14.12363","volume":"9","author":"EA Rahal","year":"2010","unstructured":"Rahal EA, Henricksen LA, Li Y, Williams RS, Tainer JA, Dixon K (2010) ATM regulates Mre11-dependent DNA end-degradation and microhomology-mediated end joining. Cell Cycle 9(14):2866\u20132877 Epub 20100712. https:\/\/doi.org\/10.4161\/cc.9.14.12363","journal-title":"Cell Cycle"},{"issue":"11","key":"9205_CR42","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.tibs.2015.08.006","volume":"40","author":"A Sfeir","year":"2015","unstructured":"Sfeir A, Symington LS (2015) Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway? Trends Biochem Sci 40(11):701\u2013714 Epub 20151001. doi: 10.1016\/j.tibs.2015.08.006. PubMed PMID: 26439531; PubMed Central PMCID: PMC4638128","journal-title":"Trends Biochem Sci"},{"key":"9205_CR43","doi-asserted-by":"publisher","unstructured":"Caracciolo D, Riillo C, Di Martino MT, Tagliaferri P, Tassone P (2021) Alternative non-homologous end-joining: error-prone dna repair as cancer\u2019s achilles\u2019 heel. Cancers (Basel) 13(6). https:\/\/doi.org\/10.3390\/cancers13061392. PubMed PMID: 33808562; PubMed Central PMCID: PMC8003480","DOI":"10.3390\/cancers13061392"},{"issue":"7538","key":"9205_CR44","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature14184","volume":"518","author":"R Ceccaldi","year":"2015","unstructured":"Ceccaldi R, Liu JC, Amunugama R, Hajdu I, Primack B, Petalcorin MI et al (2015) Homologous-recombination-deficient tumours are dependent on Pol\u03b8-mediated repair. Nature 518(7538):258\u2013262 Epub 20150202. https:\/\/doi.org\/10.1038\/nature14184","journal-title":"Nature"},{"issue":"1","key":"9205_CR45","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1038\/s41467-019-12272-9","volume":"10","author":"SJ Black","year":"2019","unstructured":"Black SJ, Ozdemir AY, Kashkina E, Kent T, Rusanov T, Ristic D et al (2019) Molecular basis of microhomology-mediated end-joining by purified full-length Pol\u03b8. Nat Commun 10(1):4423 Epub 20190927. https:\/\/doi.org\/10.1038\/s41467-019-12272-9","journal-title":"Nat Commun"},{"issue":"6","key":"9205_CR46","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1080\/10428194.2018.1542144","volume":"60","author":"A Mareckova","year":"2019","unstructured":"Mareckova A, Malcikova J, Tom N, Pal K, Radova L, Salek D et al (2019) ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. Leuk Lymphoma 60(6):1420\u20131428 PubMed PMID: 30626249","journal-title":"Leuk Lymphoma"},{"key":"9205_CR47","doi-asserted-by":"publisher","first-page":"1068110","DOI":"10.3389\/fonc.2023.1068110","volume":"13","author":"NA Borja","year":"2023","unstructured":"Borja NA, Silva-Smith R, Huang M, Parekh DJ, Sussman D, Tekin M, Atypical (2023) Front Oncol 13:1068110 Epub 20230214. doi: 10.3389\/fonc.2023.1068110. PubMed PMID: 36865800; PubMed Central PMCID: PMC9971806","journal-title":"Front Oncol"},{"issue":"23","key":"9205_CR48","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1158\/1078-0432.CCR-23-1122","volume":"29","author":"NI Vokes","year":"2023","unstructured":"Vokes NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, Trevi\u00f1o S, Druker V et al (2023) ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clin Cancer Res 29(23):4958\u20134972. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1122 PubMed PMID: 37733794; PubMed Central PMCID: PMC10690143","journal-title":"Clin Cancer Res"},{"issue":"9","key":"9205_CR49","doi-asserted-by":"publisher","first-page":"e1911895","DOI":"10.1001\/jamanetworkopen.2019.11895","volume":"2","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen G, Li J, Huang YY, Li Y, Lin J et al (2019) Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer. JAMA Netw Open 2(9):e1911895 Epub 20190904. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11895","journal-title":"JAMA Netw Open"},{"key":"9205_CR50","doi-asserted-by":"publisher","unstructured":"Karmokar A, Sargeant R, Hughes AM, Baakza H, Wilson Z, Talbot S et al (2023) Relevance of ATM status in driving sensitivity to DNA damage response inhibitors in patient-derived xenograft models. Cancers (Basel) 15(16). https:\/\/doi.org\/10.3390\/cancers15164195","DOI":"10.3390\/cancers15164195"},{"issue":"11","key":"9205_CR51","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","volume":"80","author":"S Rafiei","year":"2020","unstructured":"Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J et al (2020) Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res 80(11):2094\u20132100 Epub 20200303. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3126","journal-title":"Cancer Res"},{"issue":"36","key":"9205_CR52","doi-asserted-by":"publisher","first-page":"57714","DOI":"10.18632\/oncotarget.9757","volume":"7","author":"LC Villaruz","year":"2016","unstructured":"Villaruz LC, Jones H, Dacic S, Abberbock S, Kurland BF, Stabile LP et al (2016) ATM protein is deficient in over 40% of lung adenocarcinomas. Oncotarget 7(36):57714\u201357725. https:\/\/doi.org\/10.18632\/oncotarget.9757 PubMed PMID: 27259260; PubMed Central PMCID: PMC5295384","journal-title":"Oncotarget"},{"issue":"9","key":"9205_CR53","doi-asserted-by":"publisher","first-page":"e31885","DOI":"10.1002\/pbc.31885","volume":"72","author":"S Catueno","year":"2025","unstructured":"Catueno S, Ramakrishnan R, Elitzur S, Garcia MB, McCall D, Nunez C et al (2025) Lymphoid Malignancies in Ataxia-Telangiectasia: Experience with Novel Targeted Therapies. Pediatr Blood Cancer 72(9):e31885 Epub 20250702. https:\/\/doi.org\/10.1002\/pbc.31885","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"9205_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/pbc.24696","volume":"61","author":"JT Sandlund","year":"2014","unstructured":"Sandlund JT, Hudson MM, Kennedy W, Onciu M, Kastan MB (2014) Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. Pediatr Blood Cancer 61(2):360\u2013362 Epub 20130730. https:\/\/doi.org\/10.1002\/pbc.24696","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"9205_CR55","doi-asserted-by":"publisher","first-page":"e83304","DOI":"10.7759\/cureus.83304","volume":"17","author":"SAM Alqarni","year":"2025","unstructured":"Alqarni SAM, Al Murayeh LM, Mushari BY, Alotaibi NH (2025) The Use of Bone Marrow Transplantation (BMT) or Hematopoietic Stem Cell Transplantation (HSCT) in Pediatric Patients Diagnosed With Ataxia-Telangiectasia: A Systematic Review. Cureus 17(5):e83304 Epub 20250501. https:\/\/doi.org\/10.7759\/cureus.83304","journal-title":"Cureus"},{"key":"9205_CR56","doi-asserted-by":"publisher","unstructured":"Pastorczak A, Attarbaschi A, Bomken S, Borkhardt A, van der Werff Ten Bosch J, Elitzur S et al (2022) Consensus recommendations for the clinical management of hematological malignancies in patients with DNA double stranded break disorders. Cancers (Basel) 14(8). https:\/\/doi.org\/10.3390\/cancers14082000","DOI":"10.3390\/cancers14082000"},{"issue":"11","key":"9205_CR57","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1182\/blood.2024024283","volume":"144","author":"S Elitzur","year":"2024","unstructured":"Elitzur S, Shiloh R, Loeffen JLC, Pastorczak A, Takagi M, Bomken S et al (2024) ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies. Blood 144(11):1193\u20131205. https:\/\/doi.org\/10.1182\/blood.2024024283 PubMed PMID: 38917355; PubMed Central PMCID: PMC13122324","journal-title":"Blood"},{"issue":"2","key":"9205_CR58","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1365-2249.2008.03684.x","volume":"153","author":"ER Staples","year":"2008","unstructured":"Staples ER, McDermott EM, Reiman A, Byrd PJ, Ritchie S, Taylor AM et al (2008) Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene. Clin Exp Immunol 153(2):214\u2013220 Epub 20080526. https:\/\/doi.org\/10.1111\/j.1365-2249.2008.03684.x","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"9205_CR59","doi-asserted-by":"publisher","first-page":"O656","DOI":"10.1111\/1469-0691.12573","volume":"20","author":"C Bodemer","year":"2014","unstructured":"Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S et al (2014) Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Clin Microbiol Infect 20(10):O656\u2013O663 Epub 20140305. https:\/\/doi.org\/10.1111\/1469-0691.12573","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"9205_CR60","first-page":"9864","volume":"16","author":"F Le Lay","year":"2024","unstructured":"Le Lay F, Deparis M, Fraitag S, Dompmartin A (2024) Rubella virus vaccine-induced granulomas: a case in children with ataxia-telangiectasia. Dermatol Rep 16(4):9864 Epub 20240411. doi: 10.4081\/dr.2024.9864. PubMed PMID: 39669881; PubMed Central PMCID: PMC11635345","journal-title":"Dermatol Rep"},{"key":"9205_CR61","doi-asserted-by":"publisher","first-page":"1255799","DOI":"10.3389\/fimmu.2023.1255799","volume":"14","author":"H Zhou","year":"2023","unstructured":"Zhou H, Ma Y, Liu F, Li B, Qiao D, Ren P et al (2023) Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment. Front Immunol 14:1255799 Epub 20230905. https:\/\/doi.org\/10.3389\/fimmu.2023.1255799","journal-title":"Front Immunol"},{"key":"9205_CR62","doi-asserted-by":"publisher","first-page":"728771","DOI":"10.3389\/fcell.2022.728771","volume":"10","author":"Q Yan","year":"2022","unstructured":"Yan Q, Zhang B, Ling X, Zhu B, Mei S, Yang H et al (2022) CTLA-4 Facilitates DNA Damage-Induced Apoptosis by Interacting With PP2A. Front Cell Dev Biol 10:728771 Epub 20220224. https:\/\/doi.org\/10.3389\/fcell.2022.728771","journal-title":"Front Cell Dev Biol"},{"key":"9205_CR63","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3389\/fgene.2020.00933","volume":"11","author":"R Yi","year":"2020","unstructured":"Yi R, Lin A, Cao M, Xu A, Luo P, Zhang J (2020) ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment. Front Genet 11:933 Epub 20200814. https:\/\/doi.org\/10.3389\/fgene.2020.00933","journal-title":"Front Genet"},{"issue":"1","key":"9205_CR64","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","volume":"386","author":"HA Tawbi","year":"2022","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E et al (2022) Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med 386(1):24\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2109970 PubMed PMID: 34986285; PubMed Central PMCID: PMC9844513","journal-title":"N Engl J Med"},{"key":"9205_CR65","doi-asserted-by":"publisher","unstructured":"Tan J, Tan H, Li Y, Targeting (2023) TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. ;12(1):62. https:\/\/doi.org\/10.1186\/s40164-023-00421-2. PubMed PMID: 37468979; PubMed Central PMCID: PMC10357734","DOI":"10.1186\/s40164-023-00421-2"},{"issue":"7","key":"9205_CR66","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41419-024-06911-3","volume":"15","author":"C Li","year":"2024","unstructured":"Li C, Wang B, Tu J, Liu C, Wang Y, Chen J et al (2024) ATM inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I. Cell Death Dis 15(7):519 Epub 20240720. https:\/\/doi.org\/10.1038\/s41419-024-06911-3","journal-title":"Cell Death Dis"},{"key":"9205_CR67","doi-asserted-by":"publisher","unstructured":"Zhang Q, Jiang L, Wang W, Huber AK, Valvo VM, Jungles KM et al (2024) Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer. JCI Insight 9(6). https:\/\/doi.org\/10.1172\/jci.insight.168824. PubMed PMID: 38376927; PubMed Central PMCID: PMC11063931","DOI":"10.1172\/jci.insight.168824"},{"key":"9205_CR68","doi-asserted-by":"publisher","first-page":"972952","DOI":"10.3389\/fped.2022.972952","volume":"10","author":"A Szczawi\u0144ska-Pop\u0142onyk","year":"2022","unstructured":"Szczawi\u0144ska-Pop\u0142onyk A, T\u0105polska-J\u00f3\u017awiak K, Schwartzmann E, Pietrucha B (2022) Infections and immune dysregulation in ataxia-telangiectasia children with hyper-IgM and non-hyper-IgM phenotypes: A single-center experience. Front Pediatr 10:972952 Epub 20221020. https:\/\/doi.org\/10.3389\/fped.2022.972952","journal-title":"Front Pediatr"},{"issue":"4","key":"9205_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1158\/2643-3230.BCD-23-0268","volume":"5","author":"M Rozenbaum","year":"2024","unstructured":"Rozenbaum M, Fluss R, Marcu-Malina V, Sarouk I, Meir A, Elitzur S et al (2024) Genotoxicity Associated with Retroviral CAR Transduction of ATM-Deficient T Cells. Blood Cancer Discov 5(4):267\u2013275. https:\/\/doi.org\/10.1158\/2643-3230.BCD-23-0268 PubMed PMID: 38747501; PubMed Central PMCID: PMC11215369","journal-title":"Blood Cancer Discov"},{"key":"9205_CR70","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP (2014) The inducible caspase-9 suicide gene system as a safety switch to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol 5:235 Epub 20141028. https:\/\/doi.org\/10.3389\/fphar.2014.00235","journal-title":"Front Pharmacol"},{"issue":"3","key":"9205_CR71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L (2020) Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19(3):185\u2013199 Epub 20200103. https:\/\/doi.org\/10.1038\/s41573-019-0051-2","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"9205_CR72","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1038\/s41591-025-03874-6","volume":"31","author":"F Locatelli","year":"2025","unstructured":"Locatelli F, Pagliara D, De Ioris MA, Becilli M, Del Baldo G, Serra A et al (2025) GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial. Nat Med 31(11):3689\u20133699 Epub 20250821. https:\/\/doi.org\/10.1038\/s41591-025-03874-6","journal-title":"Nat Med"},{"issue":"7903","key":"9205_CR73","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603(7903):934\u2013941 Epub 20220207. https:\/\/doi.org\/10.1038\/s41586-022-04489-4","journal-title":"Nature"},{"issue":"8","key":"9205_CR74","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW et al (2019) CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clin Cancer Res 25(8):2560\u20132574 Epub 20190117. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0432","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9205_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/CJI.0000000000000251","volume":"42","author":"R Teng","year":"2019","unstructured":"Teng R, Zhao J, Zhao Y, Gao J, Li H, Zhou S et al (2019) Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model. J Immunother 42(2):33\u201342 0000000000000251. PubMed PMID: 30586347; PubMed Central PMCID: PMC6382056","journal-title":"J Immunother"},{"issue":"2","key":"9205_CR76","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G et al (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2(2):112\u2013120. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0170 PubMed PMID: 24579088; PubMed Central PMCID: PMC3932715","journal-title":"Cancer Immunol Res"},{"key":"9205_CR77","doi-asserted-by":"publisher","first-page":"102175","DOI":"10.1016\/j.eclinm.2023.102175","volume":"63","author":"Q Fu","year":"2023","unstructured":"Fu Q, Zheng Y, Fang W, Zhao Q, Zhao P, Liu L et al (2023) RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. EClinicalMedicine 63:102175 PubMed PMID: 37680942; PubMed Central PMCID: PMC10480529","journal-title":"EClinicalMedicine"},{"issue":"8","key":"9205_CR78","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Liu C, Gong J, Liu D, Wang X, Zhang P et al (2024) Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results. Nat Med 30(8):2224\u20132234. https:\/\/doi.org\/10.1038\/s41591-024-03037-z. Epub 20240603. PubMed PMID: 38830992","journal-title":"Nat Med"},{"key":"9205_CR79","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.coi.2018.03.002","volume":"51","author":"N Chen","year":"2018","unstructured":"Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS (2018) Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr Opin Immunol 51:103\u2013110 Epub 20180316. https:\/\/doi.org\/10.1016\/j.coi.2018.03.002","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"9205_CR80","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrg.2017.47","volume":"18","author":"NJ O\u2019Neil","year":"2017","unstructured":"O\u2019Neil NJ, Bailey ML, Hieter P (2017) Synthetic lethality and cancer. Nat Rev Genet 18(10):613\u2013623. https:\/\/doi.org\/10.1038\/nrg.2017.47. Epub 20170626. PubMed PMID: 28649135","journal-title":"Nat Rev Genet"},{"issue":"7035","key":"9205_CR81","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913\u2013917. https:\/\/doi.org\/10.1038\/nature03443 PubMed PMID: 15829966","journal-title":"Nature"},{"key":"9205_CR82","doi-asserted-by":"publisher","unstructured":"Mar\u00e9chal A, Zou L (2013) DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 5(9). https:\/\/doi.org\/10.1101\/cshperspect.a012716. PubMed PMID: 24003211; PubMed Central PMCID: PMC3753707","DOI":"10.1101\/cshperspect.a012716"},{"issue":"10","key":"9205_CR83","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/0008-5472.CAN-13-3229","volume":"74","author":"KN Mohni","year":"2014","unstructured":"Mohni KN, Kavanaugh GM, Cortez D (2014) ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res 74(10):2835\u20132845 Epub 20140324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3229","journal-title":"Cancer Res"},{"issue":"14","key":"9205_CR84","doi-asserted-by":"publisher","first-page":"11488","DOI":"10.1021\/acs.jmedchem.4c00113","volume":"67","author":"V Previtali","year":"2024","unstructured":"Previtali V, Bagnolini G, Ciamarone A, Ferrandi G, Rinaldi F, Myers SH et al (2024) New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives. J Med Chem 67(14):11488\u201311521 Epub 20240702. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00113","journal-title":"J Med Chem"},{"issue":"25","key":"9205_CR85","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","volume":"39","author":"RL Lloyd","year":"2020","unstructured":"Lloyd RL, Wijnhoven PWG, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K et al (2020) Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 39(25):4869\u20134883 Epub 20200523. https:\/\/doi.org\/10.1038\/s41388-020-1328-y","journal-title":"Oncogene"},{"key":"9205_CR86","doi-asserted-by":"publisher","first-page":"1706837","DOI":"10.3389\/fonc.2025.1706837","volume":"15","author":"Y Su","year":"2025","unstructured":"Su Y, Lu X, Bu Z, Yang X, Liu P (2025) The efficacy and safety of ATR inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Front Oncol 15:1706837 Epub 20251202. https:\/\/doi.org\/10.3389\/fonc.2025.1706837","journal-title":"Front Oncol"},{"issue":"4","key":"9205_CR87","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","volume":"16","author":"A Min","year":"2017","unstructured":"Min A, Im SA, Jang H, Kim S, Lee M, Kim DK et al (2017) AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. Mol Cancer Ther 16(4):566\u2013577 Epub 20170130. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0378","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"9205_CR88","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","volume":"127","author":"M Kwok","year":"2016","unstructured":"Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E et al (2016) ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood 127(5):582\u2013595 Epub 20151112. https:\/\/doi.org\/10.1182\/blood-2015-05-644872","journal-title":"Blood"},{"issue":"7","key":"9205_CR89","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3376","volume":"13","author":"BA Gibson","year":"2012","unstructured":"Gibson BA, Kraus WL (2012) New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 13(7):411\u2013424 Epub 20120620. https:\/\/doi.org\/10.1038\/nrm3376","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9205_CR90","doi-asserted-by":"publisher","unstructured":"Dilmac S, Ozpolat B (2023) Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches. Cancers (Basel). 15(14). https:\/\/doi.org\/10.3390\/cancers15143642. PubMed PMID: 37509303; PubMed Central PMCID: PMC10378018.","DOI":"10.3390\/cancers15143642"},{"key":"9205_CR91","doi-asserted-by":"publisher","first-page":"1380633","DOI":"10.3389\/fonc.2024.1380633","volume":"14","author":"A Muvaffak","year":"2024","unstructured":"Muvaffak A, Coleman KG (2024) PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1\/2 and RAD51 downregulation. Front Oncol 14:1380633 Epub 20240514. https:\/\/doi.org\/10.3389\/fonc.2024.1380633","journal-title":"Front Oncol"},{"issue":"2","key":"9205_CR92","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2020.10.029","volume":"79","author":"A Neeb","year":"2021","unstructured":"Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W et al (2021) Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. Eur Urol 79(2):200\u2013211 Epub 20201108. https:\/\/doi.org\/10.1016\/j.eururo.2020.10.029","journal-title":"Eur Urol"},{"key":"9205_CR93","first-page":"197","volume-title":"ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738","author":"NRRS Jette","year":"2020","unstructured":"Jette NRRS, Ye R, Yu Y, Arthur G, Goutam SBT, Kumar M, Bose P, Yip S, Kolinsky M, Lees\u2013Miller SP (2020) ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738. Springer Nature, Genome Instability & Disease, pp 197\u2013205"},{"issue":"6245","key":"9205_CR94","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/342039a0","volume":"342","author":"KL Gould","year":"1989","unstructured":"Gould KL, Nurse P (1989) Tyrosine phosphorylation of the fission yeast cdc2\u2009+\u2009protein kinase regulates entry into mitosis. Nature 342(6245):39\u201345. https:\/\/doi.org\/10.1038\/342039a0 PubMed PMID: 2682257","journal-title":"Nature"},{"issue":"4","key":"9205_CR95","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/0092-8674(87)90458-2","volume":"49","author":"P Russell","year":"1987","unstructured":"Russell P, Nurse P (1987) Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog. Cell 49(4):559\u2013567. https:\/\/doi.org\/10.1016\/0092-8674(87)90458-2 PubMed PMID: 3032459","journal-title":"Cell"},{"issue":"3","key":"9205_CR96","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1172\/JCI122622","volume":"129","author":"AB Bukhari","year":"2019","unstructured":"Bukhari AB, Lewis CW, Pearce JJ, Luong D, Chan GK, Gamper AM (2019) Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis. J Clin Invest 129(3):1329\u20131344 Epub 20190218. doi: 10.1172\/JCI122622. PubMed PMID: 30645202; PubMed Central PMCID: PMC6391092","journal-title":"J Clin Invest"},{"issue":"5","key":"9205_CR97","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","volume":"131","author":"HL Smith","year":"2024","unstructured":"Smith HL, Willmore E, Prendergast L, Curtin NJ (2024) ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors. Br J Cancer 131(5):905\u2013917 Epub 20240704. https:\/\/doi.org\/10.1038\/s41416-024-02745-0","journal-title":"Br J Cancer"},{"issue":"1","key":"9205_CR98","doi-asserted-by":"publisher","first-page":"7834","DOI":"10.1038\/s41467-023-43677-2","volume":"14","author":"GE Ronson","year":"2023","unstructured":"Ronson GE, Starowicz K, Anthony EJ, Piberger AL, Clarke LC, Garvin AJ et al (2023) Mechanisms of synthetic lethality between BRCA1\/2 and 53BP1 deficiencies and DNA polymerase theta targeting. Nat Commun 14(1):7834 Epub 20231129. https:\/\/doi.org\/10.1038\/s41467-023-43677-2","journal-title":"Nat Commun"},{"issue":"6","key":"9205_CR99","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","volume":"2","author":"J Zhou","year":"2021","unstructured":"Zhou J, Gelot C, Pantelidou C, Li A, Y\u00fccel H, Davis RE et al (2021) A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors. Nat Cancer 2(6):598\u2013610 Epub 20210617. https:\/\/doi.org\/10.1038\/s43018-021-00203-x","journal-title":"Nat Cancer"},{"key":"9205_CR100","doi-asserted-by":"publisher","unstructured":"Abeykoon JP, Asada S, Zhu G, Hirohashi Y, Moreau L, Iyer D et al (2025) Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma. J Clin Invest 135(17). https:\/\/doi.org\/10.1172\/JCI193006. PubMed PMID: 40608419; PubMed Central PMCID: PMC12404763","DOI":"10.1172\/JCI193006"},{"key":"9205_CR101","doi-asserted-by":"publisher","unstructured":"Oh G, Wang A, Wang L, Li J, Werba G, Weissinger D et al (2023) POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS\/STING signaling. J Clin Invest 133(11). https:\/\/doi.org\/10.1172\/JCI165934. PubMed PMID: 36976649; PubMed Central PMCID: PMC10232002.","DOI":"10.1172\/JCI165934"},{"issue":"2","key":"9205_CR102","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/1535-7163.MCT-22-0409","volume":"22","author":"A Simoneau","year":"2023","unstructured":"Simoneau A, Engel JL, Bandi M, Lazarides K, Liu S, Meier SR et al (2023) Ubiquitinated PCNA Drives USP1 Synthetic Lethality in Cancer. Mol Cancer Ther 22(2):215\u2013226. https:\/\/doi.org\/10.1158\/1535-7163.MCT-22-0409 PubMed PMID: 36228090; PubMed Central PMCID: PMC9891357","journal-title":"Mol Cancer Ther"},{"issue":"15","key":"9205_CR103","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-19-0761","volume":"79","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S et al (2019) Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Res 79(15):3940\u20133951 Epub 20190517. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0761","journal-title":"Cancer Res"},{"key":"9205_CR104","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-25-0641","author":"Y Kamiyama","year":"2026","unstructured":"Kamiyama Y, Sunada T, Kanoh Y, Hattahara K, Hikami K, Fukui T et al (2026) Dual inhibition of PARP and ATR induces synthetic lethal vulnerability in prostate cancer with CDK12 deficiency. Mol Cancer Ther. Epub 20260514 https:\/\/doi.org\/10.1158\/1535-7163.MCT-25-0641","journal-title":"Mol Cancer Ther"},{"issue":"7971","key":"9205_CR105","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41586-023-06277-0","volume":"619","author":"J Kim","year":"2023","unstructured":"Kim J, Woo S, de Gusmao CM, Zhao B, Chin DH, DiDonato RL et al (2023) A framework for individualized splice-switching oligonucleotide therapy. Nature 619(7971):828\u2013836 Epub 20230712. https:\/\/doi.org\/10.1038\/s41586-023-06277-0","journal-title":"Nature"},{"issue":"8","key":"9205_CR106","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/13543784.2023.2249399","volume":"32","author":"K Kuhn","year":"2023","unstructured":"Kuhn K, Lederman HM, McGrath-Morrow SA (2023) Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome. Expert Opin Investig Drugs 32(8):693\u2013704 Epub 20230828. doi: 10.1080\/13543784.2023.2249399. PubMed PMID: 37622329; PubMed Central PMCID: PMC10530584","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"9205_CR107","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1186\/s12885-025-14619-6","volume":"25","author":"G Anguera","year":"2025","unstructured":"Anguera G, Gallego O, Llobet M, Berga N, Moreno-Martinez ME, Leon X et al (2025) Opening of a phase Ib\/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma. BMC Cancer 25(1):1374 Epub 20250826. https:\/\/doi.org\/10.1186\/s12885-025-14619-6","journal-title":"BMC Cancer"},{"issue":"4","key":"9205_CR108","doi-asserted-by":"publisher","first-page":"201060","DOI":"10.1016\/j.omton.2025.201060","volume":"33","author":"A L\u00f3pez","year":"2025","unstructured":"L\u00f3pez A, Charbonnier D, Vela P, D\u00edez B, R\u00edo P, S\u00e1nchez R et al (2025) Lentiviral-mediated panErbB CAR-T cell therapy against head and neck squamous cell carcinomas for patients with Fanconi anemia. Mol Ther Oncol 33(4):201060 PubMed PMID: 41141364; PubMed Central PMCID: PMC12547774","journal-title":"Mol Ther Oncol"},{"issue":"11","key":"9205_CR109","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.bbmt.2018.07.001","volume":"24","author":"M Ussowicz","year":"2018","unstructured":"Ussowicz M, Wawrzyniak-Dzier\u017cek E, Mielcarek-Siedziuk M, Salamonowicz M, Fr\u0105czkiewicz J, Rybka B et al (2018) Allogeneic Stem Cell Transplantation after Fanconi Anemia Conditioning in Children with Ataxia-Telangiectasia Results in Stable T Cell Engraftment and Lack of Infections despite Mixed Chimerism. Biol Blood Marrow Transpl 24(11):2245\u20132249 Epub 20180707. https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.001","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"9205_CR110","doi-asserted-by":"publisher","first-page":"19386","DOI":"10.1038\/s41598-023-46332-4","volume":"13","author":"T Hirch","year":"2023","unstructured":"Hirch T, Brander N, Schenk F, P\u00f6llmann SJ, Reichenbach J, Schubert R et al (2023) Expression of a large coding sequence: Gene therapy vectors for Ataxia Telangiectasia. Sci Rep 13(1):19386 Epub 20231108. https:\/\/doi.org\/10.1038\/s41598-023-46332-4","journal-title":"Sci Rep"},{"issue":"5","key":"9205_CR111","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","volume":"40","author":"AV Anzalone","year":"2022","unstructured":"Anzalone AV, Gao XD, Podracky CJ, Nelson AT, Koblan LW, Raguram A et al (2022) Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat Biotechnol 40(5):731\u2013740 Epub 20211209. https:\/\/doi.org\/10.1038\/s41587-021-01133-w","journal-title":"Nat Biotechnol"},{"key":"9205_CR112","doi-asserted-by":"crossref","unstructured":"Rold\u00e3o A, Silva AC, Mellado MCM, Alves PM, Carrondo MJT (2017) Viruses and Virus-Like Particles in Biotechnology: Fundamentals and Applications. Compr Biotechnol 633\u2009\u2013\u200956. Copyright \u00a9 2017 Elsevier B.V. All rights reserved.","DOI":"10.1016\/B978-0-12-809633-8.09046-4"},{"issue":"19","key":"9205_CR113","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.7150\/thno.103127","volume":"14","author":"X Sun","year":"2024","unstructured":"Sun X, Lian Y, Tian T, Cui Z (2024) Virus-like particle encapsulation of functional proteins: advances and applications. Theranostics 14(19):7604\u20137622 Epub 20241104. doi: 10.7150\/thno.103127. PubMed PMID: 39659581; PubMed Central PMCID: PMC11626933","journal-title":"Theranostics"},{"key":"9205_CR114","unstructured":"Yu T (2025) Safety and efficacy of mutation-targeted precision genetic therapy for ataxia-telangiectasia (A-T) clinicaltrials.gov [Internet]: National library of medicine (US); [cited 2026 March 17, 2026]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07215416. Identifier: NCT07215416"},{"issue":"23","key":"9205_CR115","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1200\/JCO-25-00050","volume":"43","author":"RA Dineen","year":"2025","unstructured":"Dineen RA, Bowden AR (2025) Should We Screen for Malignancies in People With Ataxia Telangiectasia? J Clin Oncol 43(23):2555\u20132558 Epub 20250514. doi: 10.1200\/JCO-25-00050. PubMed PMID: 40367409","journal-title":"J Clin Oncol"},{"key":"9205_CR116","doi-asserted-by":"publisher","unstructured":"Swift M, Chase CL, Morrell D (1990) Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 46(1):21\u2009\u2013\u20097. https:\/\/doi.org\/10.1016\/0165-4608(90)90004-t. PubMed PMID: 2184933","DOI":"10.1016\/0165-4608(90)90004-t"},{"issue":"14","key":"9205_CR117","doi-asserted-by":"publisher","first-page":"e70049","DOI":"10.1002\/cam4.70049","volume":"13","author":"R Neves","year":"2024","unstructured":"Neves R, Panek R, Clarkson K, Panagioti O, Fernandez NS, Wilne S et al (2024) Feasibility of whole-body MRI for cancer screening in children and young people with ataxia telangiectasia: A mixed methods cross-sectional study. Cancer Med 13(14):e70049 PubMed PMID: 39056567; PubMed Central PMCID: PMC11273546","journal-title":"Cancer Med"},{"issue":"1","key":"9205_CR118","doi-asserted-by":"publisher","first-page":"e000592","DOI":"10.1136\/bmjonc-2024-000592","volume":"4","author":"DG Evans","year":"2025","unstructured":"Evans DG, Burghel G, Schlecht H, Sachdeva A, Hudson A, Parikh O et al (2025) UK-based clinical testing programme for somatic and germline BRCA1\/2, ATM and CDK12 mutations in prostate cancer: first results. BMJ Oncol 4(1):e000592 Epub 20250224. https:\/\/doi.org\/10.1136\/bmjonc-2024-000592","journal-title":"BMJ Oncol"},{"issue":"9","key":"9205_CR119","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1158\/1078-0432.CCR-24-2058","volume":"31","author":"AT Arafa","year":"2025","unstructured":"Arafa AT, Yadav S, Marshall CH, Mauer E, Huang M, Yilma B et al (2025) Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality. Clin Cancer Res 31(9):1730\u20131745. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2058 PubMed PMID: 40019487; PubMed Central PMCID: PMC12045718","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-026-09205-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-026-09205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:04:06Z","timestamp":1791255846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-026-09205-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":119,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9205"],"URL":"https:\/\/doi.org\/10.1007\/s12016-026-09205-y","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article is a review of previously published literature and does not contain any new studies with human participants or animals performed by the authors; therefore, ethics approval, consent to participate, and consent for publication are not applicable.","order":1,"name":"Ethics","label":"Ethical Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.M.F is a member of the Data Monitoring Committees for Encoded Therapeutics and Regenxbio.","order":2,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work, the authors used ChatGPT (OpenAI, GPT-5, 2025) to assist with initial scoping of articles, validation of findings, and to cross-check the accuracy of referenced information. The tool was not used for content generation. All text and interpretations were reviewed and verified by the authors. In addition, every reference was independently checked by the authors against the primary source, confirming the author list, title, journal, year, and the specific claim attributed to each citation; discrepancies identified during this manual audit were corrected, and automated tools were not relied upon for final citation accuracy.","order":3,"name":"Ethics","label":"Artificial Intelligence (AI)","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"83"}}